0001193125-26-257618.txt : 20260604 0001193125-26-257618.hdr.sgml : 20260604 20260604164931 ACCESSION NUMBER: 0001193125-26-257618 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260602 FILED AS OF DATE: 20260604 DATE AS OF CHANGE: 20260604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Guyer William CENTRAL INDEX KEY: 0001879013 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 261065716 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 101 REDWOOD SHORES PARKWAY CITY: REDWOOD CITY STATE: CA ZIP: 94065 4 1 ownership.xml 4 X0609 4 2026-06-02 0001088856 CORCEPT THERAPEUTICS INC CORT 0001879013 Guyer William false C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 false true false false Chief Development Officer true Common Stock 2026-06-02 4 M false 20000 21.65 A 23985 D Common Stock 2026-06-02 4 S false 20000 70.60 D 3985 D Stock Option (right to buy) 21.65 2026-06-02 4 M false 20000 0.00 D 2031-09-01 Common Stock 20000 150000 D Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.44 to $70.86 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable. The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer 2026-06-04